|1.||Minushkina, L O: 2 articles (01/2014 - 01/2012)|
|2.||Wang, Lei: 2 articles (03/2009 - 09/2008)|
|3.||Ittner, K P: 2 articles (07/2002 - 01/2000)|
|4.||Bucher, M: 2 articles (07/2002 - 01/2000)|
|5.||Krämer, B K: 2 articles (07/2002 - 01/2000)|
|6.||Zimmermann, M: 2 articles (07/2002 - 01/2000)|
|7.||Cibickova, Lubica: 1 article (12/2015)|
|8.||Caran, Tomas: 1 article (12/2015)|
|9.||Vorisek, Viktor: 1 article (12/2015)|
|10.||Cibicek, Norbert: 1 article (12/2015)|
|1.||Hypertension (High Blood Pressure)
11/01/1998 - "The antihypertensive efficacy of urapidil is similar to that of most comparators in patients with mild to moderate essential or secondary hypertension and no concomitant risk factors. "
01/01/1995 - "The beneficial effects of urapidil on hemorheology could add to its therapeutic effects in the treatment of arterial hypertension."
07/01/1993 - "Urapidil demonstrated to be effective and safe in the treatment of patients with mild and moderate arterial hypertension, showing good control of BP levels, without changing the laboratory parameters."
01/01/1988 - "Urapidil, a new alpha 1-adrenoceptor blocking drug, has been shown to be effective in the treatment of hypertension. "
06/01/1990 - "It seems that urapidil may be useful in the treatment of hypertension in dialysed patients. "
12/01/1989 - "Urapidil by itself does not impair the performance of the ischaemic myocardium, but might be beneficial in decreasing the heart rate or suppressing reflex tachycardia during reduction of the afterload."
05/01/1998 - "Urapidil works mainly by antagonizing postsynaptic alpha-1-adrenergic receptors and stimulating 5-HT1A receptors, a double mechanism that provides vasodilation with moderate decrease in blood pressure without reflex tachycardia. "
12/01/1995 - "What was striking, no reflex tachycardia was observed after i.v. administration of urapidil despite its antihypertensive action."
06/01/1994 - "Reduced arterial pressure, systemic vascular resistance and preload after urapidil 0.4 mg kg-1 i.v., associated with lack of prolonged tachycardia and preserved global left ventricular performance, may have obvious clinical implications in anaesthesia."
01/01/1994 - "We started i.v. treatment with urapidil at a diastolic blood pressure of more than 100 mm Hg. We observed a declining blood pressure in all cases without any tachycardia or serious side effects. "
09/01/2008 - "(2) Nitroglycerin, nicorandil and urapidil were more effective in preventing RA spasm than diltiazem."
01/01/1987 - "Investigations in spontaneously breathing guinea pigs showed a greater efficacy of urapidil than that of diphenhydramine in protecting the animals against histamine-induced bronchospasms, whereas acetylcholine-induced spasms were only moderately inhibited. "
09/01/2001 - "[Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns]."
12/01/1999 - "[Pre-eclampsia and treatment with urapidil]."
02/01/1998 - "The reduction of intracerebral pressure could be an additional advantage of urapidil in the treatment of patients with pre-eclampsia."
02/01/1998 - "In an earlier pilot study we examined the dose range for i.v. application of urapidil necessary for adequate blood pressure control in patients with pre-eclampsia. "
01/01/1994 - "Further studies will have to classify the rank of urapidil in the treatment of hypertension in preeclampsia."
08/01/2015 - "Both NG and urapidil significantly reduced FPG levels in multifactor heart failure patients with DM. "
06/01/1997 - "The combination of urapidil with an ACE inhibitor in the treatment of severe chronic congestive heart failure does not seem to offer any advantages over therapy with an ACE inhibitor alone and may have potentially harmful effects."
06/01/1997 - "To evaluate the effects of a combined therapy on quality of life, exercise tolerance, and hemodynamic parameters, patients with severe heart failure (New York Heart Association classes III and IV, ejection fraction below 35%) who were on ACE inhibitor therapy were randomly assigned to additional double-blind treatment with urapidil (60-120 mg/d) or placebo for 12 weeks. "
12/01/1988 - "Urapidil has been successfully administered also in patients with congestive heart failure and in hypertensive crises during or following surgical procedures; in all these conditions urapidil lowers total peripheral resistance, but blood pressure is lowered only in patients with hypertensive crises and no clinically relevant reduction in blood pressure is found in patients with congestive heart failure. "
01/01/1988 - "The increase in cardiac output with decreasing peripheral resistance and LV pressures suggests that urapidil may be useful in the therapy of congestive heart failure."
|4.||Clonidine (ST 155)
|8.||Nitroprusside (Sodium Nitroprusside)
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|5.||Cardiopulmonary Bypass (Heart-Lung Bypass)